These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 39380740)
41. Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems. Ma R; Wang Q; Meng D; Li K; Zhang Y BMC Cancer; 2021 Jan; 21(1):38. PubMed ID: 33413213 [TBL] [Abstract][Full Text] [Related]
42. Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database. Yang Q; Wang J; Wang M; Zhang S; He QQ BMC Pharmacol Toxicol; 2024 Sep; 25(1):64. PubMed ID: 39267168 [TBL] [Abstract][Full Text] [Related]
43. Ocular adverse events with immune checkpoint inhibitors. Fang T; Maberley DA; Etminan M J Curr Ophthalmol; 2019 Sep; 31(3):319-322. PubMed ID: 31528768 [TBL] [Abstract][Full Text] [Related]
44. Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors. Kawada K; Ishida T; Jobu K; Morisawa S; Tamura N; Sugimoto S; Okazaki M; Yoshioka S; Miyamura M Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295654 [No Abstract] [Full Text] [Related]
45. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors. Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988 [TBL] [Abstract][Full Text] [Related]
46. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review. Moore DC; Elmes JB; Arnall JR; Strassel SA; Patel JN Int Immunopharmacol; 2024 Mar; 129():111606. PubMed ID: 38359661 [TBL] [Abstract][Full Text] [Related]
47. Antibody-drug conjugates-related interstitial lung diseases: data mining of the FAERS database. Yu Z; Zhu H; Liao X Expert Opin Drug Saf; 2024 Sep; ():1-7. PubMed ID: 39228106 [TBL] [Abstract][Full Text] [Related]
48. Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database. Zhou Z; Wang C; Ying L; Jin M; Zhang F; Shi D J Clin Pharm Ther; 2021 Aug; 46(4):1148-1154. PubMed ID: 33768534 [TBL] [Abstract][Full Text] [Related]
49. Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system. Chen Y; Ren X; Dai Y; Wang Y Sci Rep; 2024 Sep; 14(1):21386. PubMed ID: 39271716 [TBL] [Abstract][Full Text] [Related]
50. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system. Xiao Z; Cao J; Wu S; Zhou T; Li C; Duan J; Yang Z; Xu F CNS Neurosci Ther; 2024 Jul; 30(7):e14862. PubMed ID: 39009505 [TBL] [Abstract][Full Text] [Related]
51. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database. Long P; Li S; Pan L; Wang Y; Chen W; Wang X Front Pharmacol; 2024; 15():1378010. PubMed ID: 38766629 [TBL] [Abstract][Full Text] [Related]
52. Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database. Fan M; Niu K; Wu X; Shi H Front Pharmacol; 2024; 15():1417596. PubMed ID: 39081961 [TBL] [Abstract][Full Text] [Related]
53. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162 [TBL] [Abstract][Full Text] [Related]
54. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system. Liang X; Xiao H; Li H; Chen X; Li Y Front Immunol; 2024; 15():1396752. PubMed ID: 38745663 [TBL] [Abstract][Full Text] [Related]
55. Prognosis of Patients With Interstitial Lung Disease Induced by Different Pharmacological Types of Anticancer Drugs. Iwashita K; Mizuno T; Kumazawa S; Imaizumi K; Yamada S Anticancer Res; 2021 May; 41(5):2563-2568. PubMed ID: 33952484 [TBL] [Abstract][Full Text] [Related]
56. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). Anand K; Ensor J; Trachtenberg B; Bernicker EH JACC CardioOncol; 2019 Dec; 1(2):172-178. PubMed ID: 34396179 [TBL] [Abstract][Full Text] [Related]
57. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system. Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273 [TBL] [Abstract][Full Text] [Related]
58. Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study. Li N; Feng Y; Chen X; Li Y; Zhang C; Yin Y Front Pharmacol; 2023; 14():1213608. PubMed ID: 38026965 [No Abstract] [Full Text] [Related]
59. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173 [TBL] [Abstract][Full Text] [Related]
60. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020. Jedlowski PM; Jedlowski MF; Fazel MT Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]